Skip to main content
. 2023 Aug 22;12(9):1912–1922. doi: 10.21037/tlcr-23-160

Table 2. Adverse event.

Adverse events Grade 1, n (%) Grade 2, n (%) Grade 3, n (%)
Paresthesia 37 (35.9) 19 (18.4) 2 (1.9)
Muscle cramping 22 (21.4) 2 (1.9)
Rash 18 (17.5) 9 (8.7) 2 (1.9)
Bilirubin elevation 1 (1.0)
Diarrhea 15 (14.6) 2 (1.9)
Pruritus 13 (12.6) 5 (4.9)
Headache 10 (9.7) 3 (2.9)
Fatigue 6 (5.8) 6 (5.8)
Anorexia 4 (3.9) 5 (4.9)
Nausea 5 (4.9) 2 (1.9)
Dizziness 6 (5.8) 1 (1.0)
Edema 4 (3.9) 1 (1.0)
Nail change 3 (2.9) 1 (1.0)
Mucositis 3 (2.9) 1 (1.0)
Pneumonitis 1 (1.0) 1 (1.0)
Myalgia 7 (6.8)
AST/ALT elevation 2 (1.9)

AST, aspartate aminotransferase; ALT, alanine aminotransferase.